相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
The Coming of Age of Preclinical Models of MDS
Wei Liu et al.
FRONTIERS IN ONCOLOGY (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades et al.
BLOOD ADVANCES (2022)
Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry
Rami S. Komrokji et al.
BLOOD (2021)
The Natural History of Lower Risk MDS: Factors Predicting Progression to HighRisk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
Akriti G. Jain et al.
BLOOD (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Mikkael A. Sekeres et al.
LEUKEMIA (2021)
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Amer M. Zeidan et al.
FUTURE ONCOLOGY (2021)
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S. Komrokji et al.
CANCER MEDICINE (2021)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
Aziz Nazha et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis
Shelby Corman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes
Charlotte K. Brierley et al.
CANCER (2020)
Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study
Gregory A. Abel et al.
BLOOD (2020)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U. Platzbecker et al.
BLOOD (2019)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance between Local and Central Review in the NHLBI MDS Natural History Study
Ling Zhang et al.
BLOOD (2018)
Frailty and the management of hematologic malignancies
Gregory A. Abel et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Mikkael A. Sekeres et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Call for Action: Increasing Enrollment of Untreated Patients With Higher-Risk Myelodysplastic Syndromes in First-Line Clinical Trials
Amer M. Zeidan et al.
CANCER (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
CANCER (2017)
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M. Zeidan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Red blood cell transfusion triggers in acute leukemia: a randomized pilot study
Amy E. DeZern et al.
TRANSFUSION (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
Elias J. Jabbour et al.
CANCER (2015)
Transfusion Threshold of 7 g per Deciliter - The New Normal
Paul C. Hebert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock
Lars B. Holst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
Uwe Platzbecker et al.
LEUKEMIA RESEARCH (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
Luca Malcovati et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery
Jeffrey L. Carson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
